Chronic obstructive pulmonary disease (COPD)

What changes during this transition

COPD is a defined clinical disease — post-bronchodilator spirometry FEV1/FVC <0.7 confirms airflow obstruction, GOLD 2024 stages 1–4 grade severity by FEV1% predicted, and the GOLD ABE classification (formerly ABCD) groups patients by symptom burden (mMRC, CAT) and exacerbation history. Roughly 16 million US adults are diagnosed; meaningfully more are undiagnosed. Cigarette smoking is the dominant cause; biomass-fuel exposure is a major cause globally; occupational dust and chemical exposures contribute; alpha-1 antitrypsin deficiency is the genetic minority cause that warrants screening in early-onset or family-history presentations. It is distinct from asthma (reversible airflow obstruction, Type 2 inflammation pattern, different pharmacotherapy), from obstructive sleep apnea (mechanical airway-collapse disease, separate substrate axis), and from post-COVID respiratory sequelae (separate substrate axis). Standard-of-care is well-established and deep. Smoking cessation is the only intervention that meaningfully modifies disease course and reduces FEV1 decline trajectory; every visit in COPD care should be a cessation-support visit for any current smoker, with varenicline, bupropion, nicotine replacement, and behavioral support all in the toolkit. Bronchodilator therapy is the pharmacologic foundation: SABA (albuterol) and SAMA (ipratropium) for rescue; LABA (salmeterol, formoterol, indacaterol, vilanterol, olodaterol) and LAMA (tiotropium, umeclidinium, glycopyrrolate) for maintenance; LABA/LAMA combinations (Anoro, Stiolto, Utibron) preferred for moderate disease. Inhaled corticosteroids (ICS) layer on for frequent-exacerbator phenotype, particularly with elevated blood eosinophils (≥300/μL favors ICS benefit), and triple ICS/LABA/LAMA therapy (Trelegy, Breztri) has the IMPACT 2018 and ETHOS 2020 trial evidence for reducing exacerbations and mortality in frequent exacerbators. Roflumilast (Daliresp) for severe chronic bronchitis since 2011; ensifentrine (Ohtuvayre) FDA-approved June 2024 for COPD maintenance per ENHANCE-1/2 — first new bronchodilator mechanism in decades; dupilumab (Dupixent) FDA-approved September 2024 for eosinophilic Type 2 phenotype per BOREAS/NOTUS, reducing exacerbations ~30%. Pulmonary rehabilitation is Tier 1 for symptomatic disease. Vaccinations non-optional: annual flu, PCV20, RSV (Arexvy/Abrysvo for ≥60), COVID per current schedule. Long-term oxygen if SpO2 ≤88% per NOTT 1980 / MRC 1981 mortality benefit. Alpha-1 antitrypsin screening for early-onset; augmentation therapy (Aralast, Glassia, Prolastin-C, Zemaira) for confirmed deficiency. Surgical: lung volume reduction (NETT 2003), lung transplant. Where Juno's library fits — narrowly, with an honest editorial register that says peptides don't fit well here. Semaglutide is surfaced ONLY as the obesity / cardiovascular indication for the obese-COPD subpopulation where weight loss improves dyspnea, exercise capacity, and OSA-overlap pressures through the obesity mechanism — NOT as a pulmonary therapeutic, with no semaglutide COPD trial and no GOLD listing. That surfacing carries the load-bearing safety thread that COPD cachexia and sarcopenia are real mortality predictors in severe disease, weight loss on a GLP-1 in already-sarcopenic patients needs explicit protein and pulmonary rehab scaffolding, and smoking cessation's post-cessation weight gain should never be discouraged by GLP-1 access. What is NOT surfaced and why. Thymosin alpha-1: Chinese clinical literature shows modest exacerbation-frequency reduction in frequent-exacerbator phenotype, but independent replication outside that source jurisdiction is absent, GOLD 2024 does not include it, and the dupilumab September 2024 approval for the Type 2 phenotype is where the immune-modulation conversation has actually moved — substrate exists for /ask honesty when users probe TA-1, not as discovery elevation. BPC-157: the Sikiric Zagreb corpus is gastric mucosa and tendon/ligament rodent work, not airway disease — zero COPD preclinical model, zero human trial, and inhaled / nebulized BPC-157 from compounding pharmacies has no PK, sterility, or efficacy data; substrate is a hard redirect to the actual ladder. CJC-1295: the COPD-cachexia community framing is real-mechanism on paper, but the older GH-replacement literature in COPD (Burdet 1997, Pape 1991, Casaburi 1995) already showed disappointing functional translation, the chronic-steroid-overlap insulin-resistance stacking is mechanistically poor in steroid-dependent COPD, and the standard-of-care answer for COPD sarcopenia is pulmonary rehab + resistance training + protein — substrate redirects to that ladder. Glutathione: the oxidative-stress mechanism is real but the trial portfolio specifically for glutathione is thin — the closest evidence base is NAC (PANTHEON 2014, PEACE 2008) for the same biology, several European jurisdictions carry NAC as standard-of-care chronic bronchitis adjunct, and direct glutathione supplementation has bioavailability and delivery problems NAC doesn't share; substrate exists to redirect antioxidant-curious users to the more honest NAC conversation.